Form 4: Atara Biotherapeutics Director Matthew Fust Receives Equity Grant Amidst Reverse Stock Split Context

Atara Biotherapeutics Director Matthew Fust was granted 7,828 restricted stock units on June 10, 2025, increasing his beneficial ownership to 18,188 shares, following a 1:25 reverse stock split effected in June 2024.

Summary

• Matthew K. Fust, a Director of Atara Biotherapeutics, Inc. (ATRA), acquired 7,828 shares of common stock in the form of restricted stock units (RSUs) on June 10, 2025.
• The acquisition price for these RSUs was $0 per share, indicating a grant rather than a purchase.
• These restricted stock units are scheduled to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent upon Mr. Fust's continuous service to the company.
• Following this transaction, Mr. Fust's total beneficial ownership of Atara Biotherapeutics common stock stands at 18,188 shares.
• The reported beneficial ownership amount reflects the 1:25 reverse stock split implemented by Atara Biotherapeutics on June 20, 2024.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a positive for aligning management incentives with shareholder value. However, the context of a recent 1:25 reverse stock split suggests the company has faced significant stock price challenges, which introduces a degree of caution.

Positives

• The grant of restricted stock units to a director aligns management incentives with long-term shareholder value.
• The acquisition of equity by a director demonstrates continued commitment and confidence in the company's future.

Negatives

• The transaction was an equity grant ($0 price) rather than an open market purchase, which would signal a direct cash investment by the insider.
• The mention of a 1:25 reverse stock split on June 20, 2024, often indicates that the company's stock price has significantly declined, potentially reflecting underlying challenges.

Risks

• The vesting of the 7,828 restricted stock units is contingent upon Matthew K. Fust's continuous service, meaning the shares could be forfeited if his service terminates before the vesting date.
• The disclosure of a 1:25 reverse stock split, effective June 20, 2024, indicates that Atara Biotherapeutics' stock price had fallen significantly, a common sign of underlying operational or financial challenges that could persist.

Future Outlook

The acquired restricted stock units are set to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent on the director's continuous service to the company.

Industry Context

This Form 4 filing details an insider equity grant, a common practice in the biotechnology sector to align executive and director incentives with long-term company performance. The mention of a recent 1:25 reverse stock split, however, suggests the company may have faced challenges maintaining its stock price, a situation not uncommon for development-stage biotech firms that are pre-revenue or have faced clinical setbacks.

Related Party Transactions

• Acquisition of 7,828 restricted stock units by Matthew K. Fust, a Director of Atara Biotherapeutics, Inc., which constitutes a transaction with a related party as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of RSUs can lead to minor dilution but also aligns the director's interests with long-term shareholder value. The prior reverse stock split impacts the number of shares held and the per-share price.
• Employees: While not directly mentioned, RSU grants are a common form of equity compensation, potentially impacting employee retention and motivation if similar schemes are in place.

Next Steps

• Vesting of 7,828 restricted stock units on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Form 4, SEC filing, insider transaction, restricted stock units, RSU, equity grant, director, beneficial ownership, reverse stock split